Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

Gastroenterology
R ModiglianiJ Y Mary

Abstract

Steroid dependence and early relapse are frequent after a prednisolone-induces remission in Crohn's disease. The aim of this trial was to test whether mesalamine started at the onset of steroid tapering increases the rate of weaning from prednisolone and reduces the relapse rate after prednisolone cessation. One hundred fifty patients with active Crohn's disease were administered oral prednisolone (1 mg.kg(-1). day(-1)) x 3-7 weeks; 129 patients went into clinical remission and were randomized to Pentasa (4 g . day(-1)) or placebo, administered until weaning and for 1 year thereafter. Groups were similar for clinical and biological items collected initially. Weaning failure rate was 30% and 12% in the placebo and mesalamine arms, respectively. At the end of the trial, 9 of 36 patients administered placebo and 14 of 48 administered mesalamine were in remission. Both groups had similar time to relapse curves in the postweaning year; after adjusting for risk factors (high Crohn's Disease Activity Index, white blood cell count of >9 x 10(9) /l-1 at weaning, and use of a medical treatment in the month before inclusion), Pentasa was found to be superior to placebo. After a prednisolone-induces remission in Crohn's disease, mesalamine...Continue Reading

Citations

Jan 10, 2002·Clinical Microbiology Reviews·Barbara A HendricksonJudy H Cho
Aug 13, 2004·Gut·M J CarterUNKNOWN IBD Section, British Society of Gastroenterology
Feb 17, 2006·Gut·S P L TravisUNKNOWN European Crohn's and Colitis Organisation
Feb 16, 2005·Digestion·Jean-Jacques GonversFlorian Froehlich
Feb 2, 2008·Digestion·Jean-Jacques GonversFlorian Froehlich
Jan 18, 2008·World Journal of Gastroenterology : WJG·Patricia L Kozuch, Stephen B Hanauer
Jun 19, 2013·Expert Opinion on Pharmacotherapy·Valeria CriscuoliMario Cottone
Oct 1, 2007·Expert Review of Gastroenterology & Hepatology·Timothy L Zisman, Sunanda V Kane
Mar 31, 2010·Expert Review of Gastroenterology & Hepatology·Ming Valerie LinGary R Lichtenstein
Dec 11, 1997·The British Journal of Surgery·N R BorleyD P Jewell
Apr 3, 2004·Gastroentérologie Clinique Et Biologique·Thierry HigueroGuillaume Cadiot
Jun 15, 2007·The Surgical Clinics of North America·Cyrus P Tamboli
Feb 16, 2005·Alimentary Pharmacology & Therapeutics·S HanauerT Persson
Jul 6, 2004·Alimentary Pharmacology & Therapeutics·J R Bebb, B B Scott
Sep 9, 2004·Alimentary Pharmacology & Therapeutics·S B Hanauer
Sep 9, 2004·Alimentary Pharmacology & Therapeutics·M A Kamm
Jun 2, 2007·Alimentary Pharmacology & Therapeutics·A H SteinhartS P L Travis
Apr 1, 2006·Alimentary Pharmacology & Therapeutics·R Bergman, M Parkes
May 30, 2007·Journal of Digestive Diseases·Jeffry A Katz
Mar 16, 2016·Journal of Gastroenterology·Jason Orlando Dimitri MusciJan Däbritz
Aug 15, 1998·Baillière's Clinical Gastroenterology·K LeiperJ M Rhodes
Nov 24, 2004·Advanced Drug Delivery Reviews·Altamash I Qureshi, Russell D Cohen
Jul 1, 2004·IEEE Transactions on Information Technology in Biomedicine : a Publication of the IEEE Engineering in Medicine and Biology Society·Peter Z RashevMartin P Mintchev
Aug 25, 1999·Journal of the American Academy of Dermatology·M R GilsonC A Pruitt
Jun 5, 2004·Gastroenterology Clinics of North America·Sonia Friedman
Jun 5, 2004·Gastroenterology Clinics of North America·Laura E Harrell, Stephen B Hanauer
Mar 6, 2003·Best Practice & Research. Clinical Gastroenterology·Stephen B Hanauer
Feb 13, 2001·Annual Review of Medicine·S B Hanauer, T Dassopoulos
Jan 18, 2015·Current Treatment Options in Gastroenterology·Jonathan J Hansen, R Balfour Sartor
Mar 16, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Gerassimos J MantzarisGeorge Triadaphyllou
May 7, 1998·Alimentary Pharmacology & Therapeutics·W FriesG Longo
Feb 7, 2017·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·David B AlexanderHiroyuki Tsuda
May 31, 2001·Inflammatory Bowel Diseases·G R Lichtenstein
May 31, 2001·Inflammatory Bowel Diseases·P J Rutgeerts
Jul 24, 1998·Clinical Pediatrics·R Wyllie, S Sarigol
Aug 1, 1998·Inflammatory Bowel Diseases·L R Sutherland
Oct 12, 2004·Inflammatory Bowel Diseases·Gary R LichtensteinDaniel H Present
Jun 29, 2006·Inflammatory Bowel Diseases·Yann ConsignyUNKNOWN Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)
Oct 24, 2008·Inflammatory Bowel Diseases·Eric Blum, Jeffry A Katz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.